RGNT (Regentis Biomaterials) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)


RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $4.07
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials ROE % Adjusted to Book Value?

Regentis Biomaterials RGNT -1.93% 14 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Regentis Biomaterials's ROE % for the quarter that ended in Dec. 2025 was 0.00%. Regentis Biomaterials's PB Ratio for the quarter that ended in Dec. 2025 was 7.36. Regentis Biomaterials's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 0.00%.

Regentis Biomaterials ROE % Adjusted to Book Value Related Terms

Regentis Biomaterials ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Regentis Biomaterials's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regentis Biomaterials ROE % Adjusted to Book Value Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 Negative Equity 0.00

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 Negative Equity 0.00 0.00 0.00

RGNT vs MHUAF, LUCY, CUPR: ROE % Adjusted to Book Value Comparison

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regentis Biomaterials ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's ROE % Adjusted to Book Value falls into.


RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials ROE % Adjusted to Book Value Calculation

Regentis Biomaterials's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 7.36
=0.00%

Regentis Biomaterials's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 7.36
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Regentis Biomaterials (RGNT) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Regentis Biomaterials and its competitors.
Is Regentis Biomaterials' ROE % Adjusted to Book Value too high?
Regentis Biomaterials' current ROE % Adjusted to Book Value is 0.00%. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' ROE % Adjusted to Book Value compare to MHUAF and LUCY?
Regentis Biomaterials' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Regentis Biomaterials and its competitors. Regentis Biomaterials's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.07
Price